Results 221 to 230 of about 163,785 (367)

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Haemodynamic-guided and device-free shunting for heart failure with preserved ejection fraction. [PDF]

Heart
Reddy YNV, Miranda WR.
europepmc   +1 more source

HEART FAILURE WITH RECOVERED EJECTION FRACTION: A DISTINCT ENTITY WITHIN HEART FAILURE AND PRESERVED EJECTION FRACTION

, 2010
Lynn Punnoose, Parakash Pratibhu, Michael M. Givertz, Eldrin F. Lewis, Lynne W. Stevenson, Akshay S. Desai   +5 more
openalex   +1 more source

Metformin and its Potential for Heart Failure with Preserved Ejection Fraction [PDF]

, 2019
Chew, Samuel, Iskandar, Zaid, Lang, Chim, Mohan, Pradeep, Mordi, Ify, Neaogoie, Alex, Rena, Graham, Yeow, Casserene   +7 more
core   +3 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Early Echocardiographic Markers in Heart Failure with Preserved Ejection Fraction. [PDF]

J Cardiovasc Dev Dis
Tavernese A, Rizza V, Cammalleri V, Mollace R, Carresi C, Antonelli G, Cocco N, D'Antonio L, Gelfusa M, Piccirillo F, Nusca A, Ussia GP.   +11 more
europepmc   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi, Matteo Pagnesi, Rossana Corso, Antonio M. Sammartino, Daniela Tomasoni, Riccardo M. Inciardi, Carlo M. Lombardi, Marianna Adamo, Savina Nodari, Marco Metra   +9 more
wiley   +1 more source

Sexual dimorphism in animal models of heart failure with preserved ejection fraction. [PDF]

J Appl Physiol (1985)
Bauer M, Gadkari M, Martinez Yus M, Santhanam L, Steppan J.   +4 more
europepmc   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Skeletal Muscle Alterations in Different Phenotypes of Heart Failure with Preserved Ejection Fraction. [PDF]

Int J Mol Sci
Vahle B, Klädtke R, Schauer A, Bowen TS, Wisløff U, Linke A, Adams V.   +6 more
europepmc   +1 more source